Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System
NCT ID: NCT01829061
Last Updated: 2016-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
360 participants
OBSERVATIONAL
2013-04-30
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
System Accuracy and User Performance of Blood Glucose Monitoring Systems for Self-Testing in Managing Diabetes Mellitus
NCT02290067
Evaluating System Accuracy and User Performance of Omnitest® Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus
NCT02439177
Validation of a Novel Screening Test for Maternal Insulin Resistance
NCT03388697
BGM and HbA1c POC Device Evaluation
NCT06170515
System Accuracy Evaluation of 6 CE-marked Blood Glucose Monitoring System Following ISO 15197:2013
NCT02531386
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No Treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to read English
* Read, understood and signed the Informed Consent Form
* Agrees to participate and does not withdraw\\
* Either healthy (without diabetes) or has Type 1 or Type 2 diabetes
Exlcusion Criteria:
• Declines participation or withdraws before study completion
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Quotient Diagnostics Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tim Bailey, MD
Role: PRINCIPAL_INVESTIGATOR
AMCR Institute
Stephanie Svoboda, PharmD
Role: PRINCIPAL_INVESTIGATOR
Ridgeview Research
Michael Gardner, MD
Role: PRINCIPAL_INVESTIGATOR
University of Missouri-Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AMCR Institute
Escondido, California, United States
Ridgeview Research
Chaska, Minnesota, United States
University of Missouri
Columbia, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QDL Clinical Studies
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.